MENT vs RAD-140
Emerging vs Emerging
monitor Mechanism-based · 46% Both MENT and RAD-140 suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone.
Molecular Data
MENT RAD-140
Weight 288.43 Da 393.83 Da
Half-life ~40 minutes (acetate ester) ~60 hours
Type 7-alpha-methyl-19-nortestosterone (C19H28O2) Nonsteroidal selective androgen receptor modulator (C20H16ClN5O2)
Key Benefits
MENT
01 Approximately 10x more potent than testosterone, allowing effective results at very low doses (5-25 mg/day)
02 Does not cause the sexual dysfunction associated with other 19-nor compounds like nandrolone
03 Can potentially serve as a standalone base, replacing testosterone in hormone replacement protocols
04 Rapid clearance of the acetate ester allows quick dose adjustments and fast resolution of side effects upon discontinuation
05 Powerful lean mass accretion and strength gains relative to dose
06 Under investigation as a reversible male hormonal contraceptive
07 Resistance to 5-alpha reductase means it does not convert to DHT, potentially sparing hair follicles from direct DHT-mediated damage
08 Robust suppression of gonadotropins (LH/FSH), which is therapeutically useful in contraceptive applications
RAD-140
01 Potent anabolic activity in muscle tissue with high oral bioavailability
02 Tissue-selective action sparing the prostate and other androgen-sensitive organs
03 No aromatization to estrogen (no estrogen-related side effects such as water retention or gynecomastia)
04 No conversion to DHT (reduced risk of hair loss and prostate stimulation compared to testosterone)
05 Long half-life (~60 hours) permitting convenient once-daily oral dosing
06 Neuroprotective properties observed in preclinical models
07 Increased lean body mass and reduced fat mass in preclinical studies
Dosing Protocols
MENT
5-25 mg/day (acetate) / Daily or split into 2x daily (acetate ester)
TRT Replacement - Low Dose 5-10 mg/day Daily (or split into 2 injections per day)
Moderate Anabolic Protocol 10-15 mg/day Split into 2 injections per day
Higher Dose - Advanced 15-25 mg/day Split into 2 injections per day
RAD-140
10-20 mg/day / Once daily (oral)
Side Effects
MENT
Estrogen management difficulty -- 7-alpha-methyl-estradiol is harder to control with conventional aromatase inhibitors
Water retention and bloating, particularly at doses above 10 mg/day
Elevated blood pressure, often linked to water retention and estrogenic load
Mood changes including irritability, emotional sensitivity, or anxiety (frequently estrogen-related)
Profoundly suppressive of the HPG axis -- LH and FSH driven to near-zero even at low doses
Injection frequency burden (daily or twice-daily with acetate ester)
Mild acne and oily skin
Increased appetite
RAD-140
Testosterone suppression (dose-dependent, occurs in virtually all users by week 4-6)
Liver enzyme elevation (ALT, AST increases reported in clinical and anecdotal data)
Hair shedding (temporary, typically resolves after discontinuation)
Headaches (most common in the first 1-2 weeks, often transient)
Nausea (mild, usually with initial doses or on an empty stomach)
Lipid disruption (HDL suppression, LDL elevation)
Mild insomnia or sleep disturbance
Reduced libido and mood changes related to testosterone suppression
Contraindications
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males or females
Pregnancy or potential for pregnancy
Severe hepatic impairment
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled hypertension or severe cardiovascular disease
Uncontrolled heart failure
Known hypersensitivity to trestolone or any formulation components
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer, certain breast cancers not being treated under clinical supervision)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient safety data for this population)
Research Evidence
MENT RAD-140
Status Emerging Emerging
References 5 studies 5 studies
Latest 2002 July 2020
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.